Boundless Bio Implements Strategic Workforce Reduction to Enhance Operational Efficiency

Workforce Reduction:
Boundless Bio announced a "modest reduction" in its San Diego workforce as part of its efforts to streamline operations and extend its operating runway into the fourth quarter of 2026.

Reason for Reduction:
The layoffs are intended to help the company focus on its core strategic priorities, including advancing its lead clinical-stage programs, BBI-355 and BBI-825, and ensuring sufficient financial resources to achieve initial clinical proof-of-concept data readouts.

Impact on Operations:
The reduction is expected to enhance operational efficiency and ensure the company can move its lead programs through critical milestones without financial constraints.

Business Updates:
Boundless Bio provided updates on its ongoing clinical trials, including the BBI-355 POTENTIATE trial and the BBI-825 STARMAP trial, both of which are progressing with initiatives to expedite enrollment and data collection.

Financial Outlook:
The company believes that the combination of operational efficiencies and its current cash, cash equivalents, and investments will support its operations into the fourth quarter of 2026.